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Faaria Quadri, Pharm.D., BCPS; Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

Results

Background
• Atrial fibrillation (AF) is the most common cardiac
arrhythmia
• Ibutilide is a class III antiarrhythmic agent used to restore
normal sinus rhythm (NSR) in patients with AF and atrial
flutter (AFL)
• Compared to other antiarrhythmic agents, ibutilide has
demonstrated similar or superior efficacy in clinical trials
• Its use in AF and AFL is supported by guidelines with a class
1A recommendation
• Risks associated with ibutilide include QT interval
prolongation and torsades de pointes, especially in patients
with electrolyte imbalances
• A protocol for pharmacologic cardioversion has been
established to facilitate safety and efficacy of ibutilide within
Baptist Health South Florida (BHSF) hospitals

Discussion

Baseline Characteristics
Demographics
Mean age (range), years
Mean weight (range), kg
Male, n (%)

7 (19 - 91)
93 (48 - 142)
45 (71.4)

Arrhythmia, n (%)
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Atrial Flutter
Persistent Atrial Tachycardia

Purpose

44 (69.8)
10 (15.9)
8 (12.7)
1 (1.6)

N = 63

Arrhythmia for > 48 hr, n (%)

19 (30.2)

Treatment Setting, n (%)
Emergency Department
Observation
Inpatient

14 (22.2)
26 (41.3)
23 (36.5)

Ibutilide Doses Administered, n (%)
One
Two

40 (46.5)
23 (26.7)

Primary Endpoint

To assess the appropriateness of ibutilide use and to identify
opportunities for optimal patient selection and monitoring per
the FDA label and BHSF ibutilide protocol/orders

Methods

• Study Design
• Multicenter, retrospective chart review
• Per BHSF IRB, this review does not constitute human
subjects research
• Inclusion Criteria
• Age ≥ 18 years
• Administration of ibutilide between June 1st, 2018 and
May 24th, 2019
• Exclusion Criteria: None
• Primary Endpoint
• Incidence of successful conversion to NSR
• Secondary Endpoints
• Electrolyte monitoring and replacement
• Incidence of QT interval prolongation (QT interval ≥ 450
milliseconds)
• Anticoagulation therapy based on CHA2DS2-VASc score

Limitations
• Small sample size
• Inconsistent documentation of QT interval
• Unable to establish clear risk factors for QT prolongation

Unsuccessful
NSR Conversion
19/63
(30%)

Successful
NSR Conversion
44/63
(70%)

Type of
Arrhythmia
Paroxysmal AF
Persistent AF
AFL

2/10 (20)
6/8 (75)

Persistent Atrial
Tachycardia

Conclusion

• Majority of patients (54/63) received ibutilide for
cardioversion of AF
• Forty-four (69.8%) with paroxysmal AF and 10 (15.9%)
with persistent AF
• Overall, 70% of patients successfully converted to NSR,
requiring an average of 1.6 doses per patient
• 17/44 patients required two doses for conversion to NSR
• Baseline hypokalemia or hypomagnesemia was noted in
13/56 patients
• Only 10/13 had electrolytes replenished
• Although all patient were on continuous telemetry monitor,
not all had QT interval consistently documented
• QT prolongation was noted in 10 patients post-ibutilide,
with 2/10 patients missing a baseline magnesium level
• All patients (30/30) with CHA2DS2-VASc score of ≥ 2 were
prescribed anticoagulation therapy upon discharge

0/1 (0)

Disclosures

All authors have nothing to disclose concerning possible
financial or nonfinancial personal relationships with commercial
entities that may have direct or indirect interest in the subject
matter of this presentation.

Secondary Endpoints
Electrolyte Management, n (%)
• Electrolyte monitoring
• Required electrolyte replacement
• Received electrolyte replacement

Conversion
Rate
n (%)
36/44 (82)

• Ibutilide use at BHSF is consistent with current guidelines
• Paroxysmal AF and AFL were more likely to convert to NSR
with ibutilide
• Opportunities for improvement:
• Baseline electrolyte monitoring and replacement prior to
ibutilide administration
• Documentation of QT intervals
• Staff education to enhance compliance with the
established pharmacologic cardioversion protocol may
further improve effectiveness and ensure safety of
ibutilide in AF patients

56/63 (89)
13/56 (23.2)
10/13 (76.9)

QT Prolongation Post-Ibutilide, n (%)

10 (15.9)

Anticoagulation Therapy, n (%)
• CHA2DS2-VASc score of ≥ 2
• Prescribed anticoagulation
therapy upon discharge

30 (47.6)
30 (100)
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